I’m excited to announce that the nation’s largest independent specialty pharmacy, is launching AllMetRx™ – a new care management initiative powered by Patient IO.
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today the launch of AllMetRx™, a smartphone app for Diplomat caregivers and patients facing complex diseases. With AllMetRx™, real-time treatment data is captured by caregivers and patients to monitor adherence, side effects, and other pertinent clinical data which is shared with providers and stakeholders.
AllMetRx™ is powered by Patient IO, the first and only care coordination solution that can be integrated with any healthcare software system, including electronic health records and population health management programs. Patient IO helps healthcare organizations coordinate care for patients between visits, enabling more efficient, personalized care management and improved patient outcomes.
“By providing tools that empower patients and caregivers to take a more active role in their care and treatment, AllMetRx™ has the potential to become a go-to solution for managing chronic illness, reducing readmissions and unnecessary doctor visits,” said Diplomat CEO and Chairman, Phil Hagerman.
For patients and caregivers, AllMetRx™ turns a care plan into simple daily tasks, making it easy to follow treatment-specific instructions, securely message with their care team, and read educational content.
“AllMetRx™ represents Diplomat’s continued drive to put the patient first,” Hagerman said. “As a leader in specialty care, we’re dedicated in the use of thoughtful technology to continuously improve patient care and clinical adherence as well as to have the ability to share results with stakeholders. AllMetRx™ is our latest step forward.”
To learn more about Diplomat, visit www.diplomat.is.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2014 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.